I think Mike's view was that you had to spend money to make money, and that is fine if you are growing revenue quickly. I did once look at how much each sales person sold against their salary (cant recall the figure) but it was quite astounding how little they each sold. Their business model relied of rapid uptake in the US (this is already the most expensive medicine in the world, so you would think that another $350 for DyeVert would have been easy). But it wasn't - and still isn't. You would think insurers would be pushing it if it reduced hospital costs - but they don't seem to be, and you would think hospitals and doctors would be sued for not using the latest available tech to reduce complications.
When (if) they get it on the UK NHS you will know that it is truly cost effective in practice.
If you look at the current MC (about $12 million), and strip out the cash though, it is quite a cheap company now and the tech should have value to someone.
OSP Price at posting:
48.0¢ Sentiment: Sell Disclosure: Not Held
